期刊文献+

EGFR靶向药物治疗食管癌的临床研究 被引量:1

下载PDF
导出
摘要 目的探究表皮生长因子受体(EGFR)靶向药物治疗食管癌的临床效果。方法 100例食管癌患者,根据患者治疗方法的不同分为观察组和对照组,每组50例。对照组采用常规放疗,观察组采用EGFR靶向药物治疗,对两组患者治疗效果以及治疗期间不良反应的发生率进行比较分析。结果观察组治疗总有效率以及不良反应方面显著优于对照组,差异具有统计学意义(P<0.05)。结论对于食管癌患者采用EGFR靶向药物治疗,治疗效果显著,而且在治疗期间不良反应较少,减少了患者疼痛,值得临床推广应用。
作者 任萍
出处 《中国实用医药》 2016年第5期156-157,共2页 China Practical Medicine
  • 相关文献

参考文献4

二级参考文献122

  • 1陈巧云,王荣,贾正平,王业秋,刘圆圆,谢华,马骏.毛细管电泳-限制性片段长度多态性快速检测胃癌组织中P53基因点突变的方法[J].分析化学,2007,35(9):1305-1308. 被引量:11
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin,2011,61 (2) :69 -90.
  • 3Kitagawa Y, Ueda M, Ando N, et al. Further evidence for prognostic significance of epidermal growth factor receptor gone amplification in patients with esophageal squamous cell carcinoma [ J ]. Clin Cancer Res, 1996,2 (5) :909 - 914.
  • 4Wilkinson NW, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in resec- ted esophageal adenocarcinoma [ J ]. J Gastrointest Surg, 2004,8 (4) :448 -453.
  • 5Van Groeningen C, Pdchel D, Giaccone G. Gefitinib phase lI study in second line treatment of advanced esophageal cancer [ J ]. J Clin Oncol,2004,22(14S) : 4022.
  • 6Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive fac- tors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients [ J]. J Clin On- col,2006,24(10) : 1612 - 1619.
  • 7Ferry DR,Anderson M, Beddard K,et al. A phase II study of ge- fitinib monotherapy in advanced esophageal adenocarcinoma: evi- dence of gene expression, cellular, and clinical response [ J ]. Clin Cancer Res ,2007,13 ( 19 ) :5869 - 5875.
  • 8Javle M, Pande A, Iyer R, et al. Pilot study of gefitinib,oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect pre- dicts clinical response [ J ]. Am J Clin Oncol, 2008,31 (4) : 329 - 334.
  • 9Juergens RA, Gibson MK,Yang SC,et al. Phase II study of neoad- juvant and adjuvant gefitinib ( G ) with neoadjuvant chemoradio- therapy (CRT) in operable esophageal adenocarcinoma (EAC) [ J]. J Clin Oncol,2010,28(Suppl) : Abstre14532.
  • 10Dobelbower MC, Russo SM, Raisch KP, et al. Epidermal growth fac- tor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5- fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study [J]. Anticancer Drugs,2006,17(1 ) :95 - 102.

共引文献46

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部